Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-08-22 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of Restricted Share Units (RSUs) under the company's 2021 RSU Scheme. It details the number of RSUs granted, the grantees including executive directors, vesting dates, performance targets, and clawback mechanisms. The document is a formal announcement made pursuant to the Listing Rules and does not contain financial statements or detailed financial performance data. It is not a report like an annual or interim report, nor is it a call transcript or legal proceeding. It is specifically about the grant of awards (equity compensation) to employees and directors. This type of announcement fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about share-based compensation but does not fall under other more specific categories such as Director's Dealing or Share Issue/Capital Change (since no new shares are issued, but shares held by trustees are used). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (over 10,000 characters) and detailed content confirm it is not a mere report publication announcement or a short notice.
2024-08-22 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024' and contains detailed unaudited condensed consolidated financial results for the six months ended June 30, 2024. It includes financial highlights, management discussion and analysis, business review, and key milestones, all typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes actual financial data and substantive analysis, not just a summary or announcement of a report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-08-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and cancellations. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases and cancellations with dates and prices. The document is a regulatory disclosure about share capital changes, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive data. The content fits the category of a Transaction in Own Shares (POS), as it details share repurchases and cancellations by the company.
2024-08-19 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the date of a board meeting scheduled to consider and approve the unaudited interim results for the six months ended June 30, 2024, and the recommendation on the payment of an interim dividend. The document does not contain the actual interim financial results or detailed financial data but merely announces the upcoming board meeting and the intended agenda. The document length is short (1549 characters), and it explicitly states the meeting will consider and approve the interim results, indicating this is a notice rather than the report itself. According to the 'MENU VS MEAL' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-08-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in issued shares, treasury shares, share options, warrants, convertibles, and other agreements related to share issuance. It also includes information on share repurchases and cancellations. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is a regulatory filing related to share capital movements and securities. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory compliance report on share capital movements, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a direct announcement of a capital change event.
2024-08-05 English
RESULTS ESTIMATE
Earnings Release Classification · 95% confidence The document is an announcement titled 'RESULTS ESTIMATE' by Simcere Pharmaceutical Group Limited, dated July 30, 2024. It provides a preliminary assessment of the unaudited consolidated management accounts for the six months ended June 30, 2024, including expected revenue and profit figures. It explicitly states that the information is based on preliminary unaudited data and that the final interim results announcement is expected to be published later (in late August 2024). The document is not the actual interim report but a results estimate announcement, which is typical for earnings releases that provide key highlights before the full report is published. The document length is 5586 characters, which is sufficient for a detailed earnings release summary. It does not contain full financial statements or detailed analysis, so it is not an Interim/Quarterly Report (IR). It is not a full Annual Report (10-K) or any other category. Therefore, the best classification is Earnings Release (ER).
2024-07-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.